Plain-English translation of NCT06368492 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether —a naturally occurring psychedelic compound—can help reduce pain in people with fibromyalgia. You would receive very low doses (5 mg or 10 mg) designed not to cause hallucinations, along with a placebo, on separate occasions. Researchers will measure how the medication affects your pain perception using standard pain tests.
Fibromyalgia is a hard-to-treat chronic pain condition, and current therapies only provide small improvements. Early research suggests that low doses of this medication may help reduce chronic pain in other conditions, but this has never been properly studied in fibromyalgia patients under controlled conditions.
You likely qualify if…
You likely don't qualify if…
You would visit the study center three times, on separate occasions, to receive either the medication or placebo. At each visit, you would take a dose and then complete two pain tests: one involving brief contact with cold water, and another measuring your pain sensitivity to pressure. You would need to avoid certain foods and drinks beforehand, and you cannot drive or operate machines for 24 hours after each visit.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Netherlands